Pages that link to "Q95829739"
Jump to navigation
Jump to search
The following pages link to Jens Hillengass (Q95829739):
Displaying 50 items.
- Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title) (Q26782868) (← links)
- Efficacy and tolerability of the histone deacetylase inhibitor panobinostat in clinical practice. (Q33443417) (← links)
- Diffusion-weighted imaging for non-invasive and quantitative monitoring of bone marrow infiltration in patients with monoclonal plasma cell disease: a comparative study with histology (Q33881446) (← links)
- International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma (Q34450381) (← links)
- Genome-wide association study identifies multiple susceptibility loci for multiple myeloma (Q34677689) (← links)
- A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma (Q35669888) (← links)
- Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial. (Q35800851) (← links)
- Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transpla (Q35999062) (← links)
- Comparison of (18)F-FDG PET/CT and PET/MRI in patients with multiple myeloma (Q36205152) (← links)
- High-dose chemotherapy and autologous stem cell transplantation of patients with multiple myeloma in an outpatient setting. (Q36287792) (← links)
- Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma (Q36366654) (← links)
- Staging monoclonal plasma cell disease: comparison of the Durie-Salmon and the Durie-Salmon PLUS staging systems (Q37790183) (← links)
- Appearance of monoclonal plasma cell diseases in whole-body magnetic resonance imaging and correlation with parameters of disease activity (Q38202605) (← links)
- miRNAs in multiple myeloma--a survival relevant complex regulator of gene expression (Q38673891) (← links)
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma (Q38832525) (← links)
- Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group (Q39214847) (← links)
- Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. (Q39560208) (← links)
- Potential therapeutic targets in plasma cell disorders: A flow cytometry study. (Q40212706) (← links)
- Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study (Q40691084) (← links)
- Single versus tandem high-dose melphalan followed by autologous blood stem cell transplantation in multiple myeloma: long-term results from the phase III GMMG-HD2 trial (Q40845932) (← links)
- (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate (Q41201314) (← links)
- Longitudinal fluorescence in situ hybridization reveals cytogenetic evolution in myeloma relapsing after autologous transplantation. (Q41230411) (← links)
- Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement (Q41552459) (← links)
- Peripheral neuropathy associated with subcutaneous or intravenous bortezomib in patients with newly diagnosed myeloma treated within the GMMG MM5 phase III trial. (Q42335813) (← links)
- Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma - subgroup analysis of the prospective GMMG MM5 trial (Q42366623) (← links)
- Intravoxel incoherent motion imaging for assessment of bone marrow infiltration of monoclonal plasma cell diseases (Q43645989) (← links)
- Parametric histogram analysis of dynamic contrast-enhanced MRI in multiple myeloma: a technique to evaluate angiogenic response to therapy? (Q43937754) (← links)
- Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology (Q48262403) (← links)
- Analysis of long-term survival in multiple myeloma after first-line autologous stem cell transplantation: impact of clinical risk factors and sustained response (Q48338656) (← links)
- Prognostic significance of tumor burden assessed by whole-body magnetic resonance imaging in multiple myeloma patients treated with allogeneic stem cell transplantation (Q49752739) (← links)
- Infiltration patterns in monoclonal plasma cell disorders: correlation of magnetic resonance imaging with matched bone marrow histology (Q51094659) (← links)
- Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment. (Q51110235) (← links)
- Sensitivity of whole-body CT and MRI versus projection radiography in the detection of osteolyses in patients with monoclonal plasma cell disease. (Q53067210) (← links)
- Dynamic contrast-enhanced MRI for assessing the disease activity of multiple myeloma: a comparative study with histology and clinical markers. (Q53580725) (← links)
- A systematic classification of death causes in multiple myeloma. (Q55096596) (← links)
- Multiple myeloma and monoclonal gammopathy of undetermined significance: importance of whole-body versus spinal MR imaging (Q56781760) (← links)
- Bortezomib-based induction therapy with high or low-dose dexamethasone in newly diagnosed, transplant-eligible multiple myeloma (Q56967302) (← links)
- Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma (Q58743933) (← links)
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessment of Antiangiogenic Treatment Effects in Multiple Myeloma (Q64025767) (← links)
- Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging of bone marrow in healthy individuals (Q64025780) (← links)
- Prognostic Significance of Focal Lesions in Whole-Body Magnetic Resonance Imaging in Patients With Asymptomatic Multiple Myeloma (Q64025788) (← links)
- Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation (Q64025792) (← links)
- Gain of 1q21 and distinct adverse cytogenetic abnormalities correlate with increased microcirculation in multiple myeloma (Q64025793) (← links)
- Where is the primary tumour? (Q64025796) (← links)
- Lumbar Bone Marrow Microcirculation Measurements from Dynamic Contrast-Enhanced Magnetic Resonance Imaging Is a Predictor of Event-Free Survival in Progressive Multiple Myeloma (Q64025799) (← links)
- Increased microcirculation detected by dynamic contrast-enhanced magnetic resonance imaging is of prognostic significance in asymptomatic myeloma (Q87490030) (← links)
- Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial (Q89602885) (← links)
- Cytogenetic subclone formation and evolution in progressive smoldering multiple myeloma (Q91236245) (← links)
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders (Q92510769) (← links)
- Cystic transformation of focal lesions after therapy is associated with remission but adverse outcome in myeloma (Q92913420) (← links)